Last reviewed · How we verify
Moxidectin (MOXIDECTIN)
Moxidectin works by interfering with the parasite's ability to produce energy, ultimately leading to its death.
Moxidectin is a small molecule antiparasitic medication originally developed by MDGH and currently owned by the same company. It was FDA-approved in 2018 for the treatment of infection by Onchocerca volvulus, a parasitic worm that causes river blindness. Moxidectin is a patented medication with no generic manufacturers available. Key safety considerations include its potential effects on the liver and nervous system. It is off-patent, but its commercial status remains patented.
At a glance
| Generic name | MOXIDECTIN |
|---|---|
| Sponsor | Mdgh |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2018 |
Mechanism of action
Moxidectin, macrocyclic lactone, is an anthelmintic drug [see Microbiology 12.4 )].
Approved indications
- Infection by Onchocerca volvulus
Common side effects
- Eosinophilia
- Pruritus
- Musculoskeletal pain
- Headache
- Lymphocytopenia
- Tachycardia
- Rash
- Abdominal pain
- Hypotension
- Pyrexia
- Leukocytosis
- Influenza-like illness
Key clinical trials
- Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (PHASE3)
- Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
- Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis (PHASE3)
- Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases (PHASE4)
- Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC (PHASE3)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxidectin CI brief — competitive landscape report
- Moxidectin updates RSS · CI watch RSS
- Mdgh portfolio CI